Edgestream Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Edgestream Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.86M	Buy	+124,063	New	+$2.98M	0.05%	523
2026 Q1	–	Sell	-99,873	Closed	-$2.3M	–	1067
2025 Q4	$2.3M	Buy	+99,873	New	+$3.28M	0.06%	495
2023 Q2	–	Sell	-6,666	Closed	-$267K	–	879
2023 Q1	$267K	Buy	+6,666	New	+$286K	0.03%	488
2022 Q4	–	Sell	-17,111	Closed	-$709K	–	615
2022 Q3	$709K	Buy	+17,111	New	+$879K	0.05%	314

Other funds holding RARE

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Edgestream Partners's RARE Position: Q3 2026 in Review

Edgestream Partners opened a new position in Ultragenyx Pharmaceutical (RARE) in Q3 2026: 124,063 shares worth $1.86M. The stake represents 0.05% of the portfolio and ranks #523 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in RARE as recently as Q4 2025.

Edgestream Partners first reported a position in RARE in Q3 2022 and has held it in 4 quarters since. The position peaked at $2.3M in Q4 2025. 118 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

Edgestream Partners held 124,063 shares of Ultragenyx Pharmaceutical worth $1.86M as of Q3 2026.
Ultragenyx Pharmaceutical was a new Edgestream Partners position in Q3 2026.
Ultragenyx Pharmaceutical made up 0.05% of Edgestream Partners's portfolio in Q3 2026, its #523 holding.
Edgestream Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and has held it in 4 quarters since.
Edgestream Partners's Ultragenyx Pharmaceutical position peaked at $2.3M in Q4 2025.
118 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Edgestream Partners's 13F filing for Q3 2026, filed 10 Nov 2026.